Christy Jones Sells 6,430 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Key Points

• Director Christy Jones sold 6,430 Beta Bionics shares at an average of $23, generating $147,890 and reducing her holdings by 24.74% to 19,564 shares. The transaction was made under a pre-arranged Rule 10b5-1 plan.
• BBNX traded at $22.19, with a market capitalization of approximately $998 million, while the company remains unprofitable despite beating quarterly EPS expectations. Analysts have a “Moderate Buy” consensus rating and an average price target of $22.45.
• Beta Bionics announced plans to integrate its insulin-delivery systems with Senseonics’ Eversense 365 glucose monitor, targeting a fourth-quarter 2026 launch, though the company also faces securities-litigation allegations and broader regulatory and execution risks.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) Director Christy Jones sold 6,430 shares of the business's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the sale, the director owned 19,564 shares in the company, valued at approximately $449,972. The trade was a 24.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics Stock Performance

Shares of BBNX traded down $0.62 during midday trading on Wednesday, hitting $22.19. 1,396,325 shares of the company traded hands, compared to its average volume of 1,192,758. The stock has a market cap of $998.33 million, a price-to-earnings ratio of -13.45 and a beta of 3.37. The firm has a 50 day moving average of $17.88 and a 200-day moving average of $14.21. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million for the quarter. Sell-side analysts predict that Beta Bionics, Inc. will post -2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BBNX shares. Robert W. Baird lifted their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 15th. Wall Street Zen upgraded Beta Bionics from a "sell" rating to a "hold" rating in a research report on Saturday. Truist Financial reaffirmed a "buy" rating and issued a $23.00 price objective (up from $22.00) on shares of Beta Bionics in a research note on Tuesday, September 15th. Wells Fargo & Company initiated coverage on Beta Bionics in a research report on Wednesday. They set an "overweight" rating and a $28.00 target price on the stock. Finally, Bank of America increased their price target on Beta Bionics from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Tuesday, September 15th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Beta Bionics has an average rating of "Moderate Buy" and a consensus price target of $22.45.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics announced an agreement with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor. The combined iLet-Eversense system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening Beta Bionics’ competitive position in automated insulin delivery. Beta Bionics Announces Agreement to Integrate the iLet and mint with Senseonics’ Eversense 365
• Neutral Sentiment: Multiple law firms are soliciting investors to serve as lead plaintiff in the same federal securities class action. The deadline is November 3, 2026, for investors who purchased BBNX shares between July 30, 2025 and February 24, 2026. The repeated notices do not represent separate judgments against the company, but they are likely to maintain attention on the dispute. Johnson Fistel BBNX Investor Alert
• Negative Sentiment: The lawsuit alleges that Beta Bionics failed to timely disclose a June 2025 FDA Form 483 and more than 18,000 complaints related to its iLet device, and that subsequent disclosures caused sharp declines in BBNX shares. These are allegations, not established findings, but the case creates litigation costs, reputational risk and uncertainty around regulatory compliance and product demand. Levi & Korsinsky BBNX Securities Class Action Notice
• Negative Sentiment: Additional caution comes from reported insider activity: executives recorded 24 open-market sales and no purchases during the past six months. With BBNX trading well above its 200-day average and analysts’ reported median price target of $18, investors may be especially sensitive to legal and execution risks.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Beta Bionics in the 2nd quarter worth approximately $62,000. The Manufacturers Life Insurance Company bought a new position in shares of Beta Bionics during the second quarter valued at approximately $172,000. ProShare Advisors LLC bought a new position in shares of Beta Bionics during the fourth quarter valued at approximately $217,000. Finally, Ieq Capital LLC purchased a new position in Beta Bionics during the second quarter valued at approximately $229,000.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.